[1] JULIANO R L, LING V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants[J]. Biochim Biophys Acta, 1976, 455(1):152-162.
[2] WACHER V J, SALPHATI L, BENETL Z. Active secretion and enterocytic drug metabolism barriers to drug absorption[J]. Adv Drug Deliv Rev, 2001, 46(1-3):89-102.
[3] LIN J H. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein[J]. Adv Drug Deliv Rev, 2003, 55(1):53-81.
[4] BRAUN A, H?MMERLE S, SUDA K, <>et al. Cell cultures as tools in biopharmacy[J]. Eur J Pharm Sc i , 2000, 11(Suppl 2): 51-60.
[5] CHO M J, THOMPSON D P, CRAMER C T, et al. The madin darby canine kidney (MDCK) epithelial cell monolayer as a model cellular transport barrier[J]. Pharm Res, 1989, 6(1):71-77.
[6] IRVINE J D, TAKAHSHI L, LOCKHART K, et al. MDCK (Madin-Darby canine kedney) cells: A tool for membrane permeability screening[J]. J Pharm Sci, 1999, 88(1):28-33.
[7] SIMONS K, IKONEN E. Functional rafts in cell membranes[J]. Nature, 1997, 387(6633):569-572.
[8] LUKER G D, PICA C M, KUMAR A S, et al. Effects of cholesterol and enantiomeric cholesterol on P-glycoprotein localization and function in low-density membrane domains[J]. Biochemistry, 2000, 39(26):7651-7661.
[9] TANG F, HORIE K, BORCHARDT R T. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa[J]. Pharm Res, 2002, 19(6):765-772.
[10] GUMBLETON M, AUDUS K L. Progress and limitations in the use of <>in vitro cell cultures to serve as a permeability screen for the blood-brain barrier[J]. J Pharm Sci, 2001, 90(11):1681-1698.
[11] H ? MMERLE S P, ROTHEN-RUTISHAUSER B, KR ? MER S D, et al. P-Glycoprotein in cell cultures: a combined approach to study expression, localisation, and functionality in the confocal microscope[J]. Eur J Pharm Sci, 2000, 12 (1):69-77.
[12] TANG F, OUYANG H, YANG J Z, et al. Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCK-MDR1 cell monolayers[J]. J Pharm Sci, 2004, 93(5):1185-1194.
[13] MAHAR DOAN K M, HUMPHREYS J E, WEBSTER L O, et al. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs[J]. J Pharmacol Exp Ther, 2002, 303(3):1029-1037.
[14] ZHOU L, CHEN X, GU Y, et al. Transport characteristics of candesartan in human intestinal Caco-2 cell line[J]. Biopharm Drug Dispos, 2009, 30(5):259-264.
[15] ANDERLE P, NIEDERER E, RUBAS W, et al. P-glycoprotein (P-gp) mediated efflux in Caco-2 monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels[J]. J Pharm Sci, 1998, 87(6):757-762.
[16] ZHOU L, CHEN X, GU Y, et al. Transport characteristics of candesartan in human intestinal Caco-2 cell line[J]. Biopharm Drug Dispos, 2009, 30(5):259-264.
[17] ROTHEN-RUTISHAUSER B, BRAUN A, G ü NTHERT M, et al. Formation of multilayers in the Caco-2 cell culture model: a confocal laser scanning microscopy study[J]. Pharm Res , 2000, 17(4):460-465.
[18] PRIME-CHAPMAN H M, FEARN R A, COOPER A E, et al. Differential multidrug resistance-associate protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells[J]. J Pharmacol Exp Ther , 2004, 311(2):476-484.
[19] RODRIGUES A C, CURI R, GENVIGIR F C, et al. The expression of efflux and uptake transporters are regulated by statins in Caco-2 and HepG2 cells[J]. Acta Pharmacol Sin ( 中国药理学报 ) , 2009, 30(7): 956-964.
[20] WANG Y, CAO J, ZENG S. Establishment of a P-glycoprotein substrate screening model and its preliminary application [J]. World J Gastroenterol ( 世界胃肠病学 ) , 2004, 10(9):1365-1368.
[21] WANG Y, CAO J, ZENG S. Involvement of P-glycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaempferol, and isorhamnetin[J]. J Pharm Pharmacol, 2005, 57(6):751-758.
[22] W ANG Y, C AO J, WENG J H, et al . Simultaneous determination of quercetin, kaempferol and isorhamnetin accumulated human beast cancer cells, by high-performance liquid chromatography [J] . J Pharm Biomed Anal, 2005, 39(1-2):328-333.
[23] POLLI J W, WRING S A, HUMPHREYS J E, et al. Rational use of <>in vitro P-glycoprotein assays in drug discovery[J]. J Pharmacol Exp Ther, 2001, 299(2):620-628.
[24] GOH L B, SPEARS K J, YAO D, et al. Endogenous drug transporters in <>in vitro and <>in vivo models for the prediction of drug disposition in man[J]. Biochem Pharmacol, 2002, 64(11):1569-1578.
[25] LUO S, WANG Z, KANSARA V, et al. Activity of a sodium-dependent vitamin C transporter (SVCT) in MDCK-MDR1 cells and mechanism of ascorbate uptake[J]. Int J Pharm, 2008, 358(1-2):168-176.
[26] BRAVDEN D J, GRIFFIN J. Avermectin transepithelial transport in MDR1- and MRP-transfected canine kidney monolayers.[J]. Vet Res Commun, 2008, 32(1):93-106.
[27] ZHANG Y, BENET L Z. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers [J] . Pharm Res , 1998, 15(10):1520-1524.
[28] WANG Q, RAGER J D, WEINSTEIN K, et al. Evaluation of the MDR-MDCK cell line as a permeability screen for the bloodrain barrier[J]. Int J Pharm, 2005, 288(2):349-359.
[29] KARYEKAR C S, EDDINGTON N D, GARIMELLA T S, et al. Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model[J]. Pharmacotherapy, 2003, 23(4):436-442.
（ 收稿日期 ： 2009-01-04 ）